Intérêt de la kétamine dans le traitement des douleurs chroniques

Free Access

Issue		Biologie Aujourd’hui Volume 217, Number 3-4, 2023


Page(s)		145 - 149
DOI		https://doi.org/10.1051/jbio/2023019
Published online		29 novembre 2023

ANSM. (2010). Douleur rebelle en situation palliative avancée chez l’adulte – Recommandations de bonne pratique. http://ansm.sante.fr/. [Google Scholar]
ANSM. (2017). Kétamine : risque d’atteintes hépatiques graves lors d’utilisations prolongées et/ou à doses élevées – Point d’Information. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Ketamine-risque-d-atteintes-hepatiques-graves-lors-d-utilisations-prolongees-et-ou-a-doses-elevees-Point-d-Information. [Google Scholar]
Chan, E.O.T., Chan, V.W.S., Tang, T.S.T., Cheung, V., Wong, M.C.S., Yee, C.H., Ng, C.F., Teoh, J.Y.C. (2022). Systematic review and meta-analysis of ketamine-associated uropathy. Hong Kong Med J, 28, 466-474. [PubMed] [Google Scholar]
Chizh, B.A. (2007). Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol, 21, 259-271. [CrossRef] [PubMed] [Google Scholar]
Cohen, S.P., Bhatia, A., Buvanendran, A., Schwenk, E.S., Wasan, A.D., Hurley, R.W., Viscusi, E.R., Narouze, S., Davis, F.N., Ritchie, E.C., Lubenow, T.R., Hooten, W.M. (2018). Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med, 43, 456-466. [PubMed] [Google Scholar]
Cook-Sather, D., Adamson, P.C., Li, J., Hakonarson, H. (2016). CYP2B6*6 or not CYP2B6*6-that remains a question for precision medicine and ketamine! Anesthesiology, 125, 1085-1087. [CrossRef] [PubMed] [Google Scholar]
Corriger, A., Pickering, G. (2019). Ketamine and depression: a narrative review. Drug Des Devl Ther, 13, 3051-3067. [CrossRef] [Google Scholar]
Corriger, A., Voute, M., Lambert, C. Pereira, B., Pickering, G., OKAPI Consortium. (2022). Ketamine for refractory chronic pain: a 1-year follow-up study. Pain, 163, 690-701. [CrossRef] [PubMed] [Google Scholar]
Corssen, G., Domino, E.F. (1966). Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg, 45, 29-40. [Google Scholar]
Curran, H.V., Monaghan, L. (2001). In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction, 96, 749-760. [CrossRef] [PubMed] [Google Scholar]
Grégoire, M.C., MacLellan, D.L., Finley, G.A. (2008). A pediatric case of ketamine-associated cystitis (letter-to-the-Editor RE: Shahani, R., Streutker, C., Dickson, B., et al. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69, 810-812, 2007). Urology, 71, 1232-1233. [CrossRef] [Google Scholar]
Hashimoto, K. (2012). A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action. Clin Psychopharmacol Neurosci, 10, 59-60. [CrossRef] [PubMed] [Google Scholar]
Heinzel, A., Steinke, R., Poeppel, T.D., Grosser, O., Bogerts, B., Otto, H., Northoff, G. (2008). S-ketamine and GABA-A-receptor interaction in humans: an exploratory study with I-123-iomazenil SPECT. Hum Psychopharmacol, 23, 549-554. [CrossRef] [PubMed] [Google Scholar]
Hirota, K., Okawa, H., Appadu, B.L., Grandy, D.K., Devi, L.A., Lambert, D.G. (1999). Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology, 90, 174-182. [CrossRef] [PubMed] [Google Scholar]
Huang, M.C., Chen, C.H., Liu, T.H., Chung, A.N., Liu, Y.L., Quednow, B.B., Bavato, F. (2023). Comorbidity of ketamine dependence with major depressive disorder increases the vulnerability to neuroaxonal pathology. J Psychiatr Res, 158, 360-364. [CrossRef] [PubMed] [Google Scholar]
Jonkman, K., Dahan, A., van de Donk, T., Aarts, L., Niesters, M., van Velzen, M. (2017). Ketamine for pain. F1000Res 6. pii: F1000 Faculty Rev-1711. [Google Scholar]
Lodge, D., Anis, N.A., Burton, N.R. (1982). Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine. Neurosci Lett, 29, 281-286. [CrossRef] [PubMed] [Google Scholar]
Loo, C. (2018). Can we confidently use ketamine as a clinical treatment for depression? Lancet Psychiatry 5, 11-12. [CrossRef] [PubMed] [Google Scholar]
Maher, D.P., Chen, L., Mao, J. (2017). Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg, 124, 661-674. [CrossRef] [PubMed] [Google Scholar]
Meshkat, S., Rodrigues, N.B., Di Vincenzo, J.D. (2021). Pharmacogenomics of ketamine: a systematic review. J Psychiatr Res, 145, 27-34. [Google Scholar]
Mion, G., Villevieille, T. (2013). Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther, 19, 370-380. [CrossRef] [PubMed] [Google Scholar]
Moisset, X., Bouhassira, D., Avez Couturier, J., Alchaar, H., Conradi, S., Delmotte, M.H., Lanteri-Minet, M., Lefaucheur, J.P., Mick, G., Piano, V., Pickering, G., Piquet, E., Regis, C., Salvat, E., Attal, N. (2020). Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Revue neurologique, 176, 325-352. [CrossRef] [PubMed] [Google Scholar]
Niesters, M., Martini, C., Dahan, A. (2014). Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol, 77, 357-367. [CrossRef] [PubMed] [Google Scholar]
Orhurhu, V.J., Roberts, J.S., Ly, N., Cohen, S.P., Ketamine in acute and chronic pain management, in: StatPearls [Internet], StatPearls Publishing, Treasure Island (FL), 2022. PMID: 30969646. [Google Scholar]
Peltoniemi, M.A., Hagelberg, N.M., Olkkola, K.T., Saari, T.I. (2016). Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet, 55, 1059-1077. [CrossRef] [PubMed] [Google Scholar]
Peskin, E., Gudin, J., Schatman, M.E. (2023). Increased demand for ketamine infusions and associated complexities. J Pain Res, 16, 295-299. [CrossRef] [Google Scholar]
Pfenninger, E.G., Durieux, M.E., Himmelseher, S. (2002). Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology, 96, 357-366. [CrossRef] [PubMed] [Google Scholar]
Pickering, G., Morel, V., Micallef, J. (2018). Ketamine and chronic pain: a narrative review of its efficacy and its adverse events. Thérapie, 73, 529-539. [CrossRef] [Google Scholar]
Pickering, G., Pereira, B., Morel, V., Corriger, A., Giron, F., Marcaillou, F., Bidar-Beauvallot, A., Chandeze, E., Lambert, C., Bernard, L., Delage, N. (2020). Ketamine and magnesium for refractory neuropathic pain: a randomized, double-blind, crossover trial. Anesthesiology, 133, 154-164. [CrossRef] [PubMed] [Google Scholar]
Sears, B.E. (1975). Experience with ketamine anesthesia. J Natl Med Assoc, 67, 32-35. [PubMed] [Google Scholar]
Seeman, P., Ko, F, Tallerico, T. (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry, 10, 877-883. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
SFETD. (2019). https://www.sfetd-douleur.org/guides-des-bonnes-pratiques/Novembre2019. [Google Scholar]
Shahani, R., Stewart, R.J. (2008). Reply to letter-to-the-Editor [Re: Shahani, R., Streutker, C., Dickson, B. (2007). Ketamine-associated ulcerative cystitis: a new clinical entity. Urology, 69, 810-812] Urology, 71, 987. [CrossRef] [Google Scholar]
Short, B., Fong, J., Galvez, V., Shelker, W., Loo, K. (2018). Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry, 5, 65-78. [CrossRef] [PubMed] [Google Scholar]
Sinner, B., Graf, B.M. (2008). Ketamine. Handb Exp Pharmacol, 182, 313-333. [CrossRef] [Google Scholar]
Suzuki, M., Edmonds, H.L. Jr, Tsueda, K., Malkani, A.L., Roberts, C.S. (1998). Effect of ketamine on bispectral index and levels of sedation. J Clin Monit Comput, 14, 373. [CrossRef] [PubMed] [Google Scholar]
Turkish, A., Luo, J.J., Lefkowitch, J.H. (2013). Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis. Hepatology, 58, 825-827. [CrossRef] [PubMed] [Google Scholar]
Voute, M., Riant, T., Amodéo, J.M., André, G., Barmaki, M., Collard, O., Colomb, C., Créac’h, C., Deleens, R., Delorme, C., de Montgazon, G., Dixneuf, V., Dy, L., Gaillard, J., Gov, C., Kieffer, X., Lanteri-Minet, M., Le Borgne, J.M., Le Caër, F., Maamar, F., Maindet, C., Marcaillou, F., Plantevin, F., Pluchon, Y.M., Rioult, B., Rostaing, S., Salvat, E., Sep Hieng, V., Sorel, M., Vergne-Salle, P., Morel, V., de Chazeron, I., Pickering, G. (2022). Ketamine in chronic pain: a Delphi survey. Eur J Pain, 26, 873-887. [CrossRef] [PubMed] [Google Scholar]
Yanagihara, Y., Ohtani, M., Kariya, S., Uchino, K., Hiraishi, T., Ashizawa, N. (2003). Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos, 24, 37-43. [CrossRef] [PubMed] [Google Scholar]
Zukin, S.R., Fitz-Syage, M.L., Nichtenhauser, R., Zukin, R.S. (1983). Specific binding of [³H] phencyclidine in rat central nervous tissue: further characterization and technical considerations. Brain Res, 258, 277-284. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.